Alaunos Therapeutics, Inc., formerly known as TCR2 Therapeutics Inc., is a forward-thinking biotechnology company mainly focused on cancer immunology. Implicit in each subsidiary's name— 'Alaunos'— is the pioneering mission at its core: "to bring light into darkness," which both encapsulates its innovative drive and anticipates a brighter future for all who grapple with infirmity.
Founded in 2015, Alaunos' headquarters is in Cambridge, Massachusetts. The company operates with an underlying commitment to improve the lives of patients fighting cancer by developing cutting-edge, technologically sophisticated, 'off-the-shelf' cell therapies. Excellent science is the solid foundation upon which Alaunos has constructed its platform for curative treatments.
Alaunos' flagship technology is the TRuC-T cells—a novel class of T-cell therapies for patients suffering from solid tumors. Leveraging potent T-cell activation, these therapies possess the potential to step up as unparalleled weaponries against nefarious cancerous developments. TRuC-T cells, being "off-the-shelf", provide an opportunity for all patients, regardless of HLA type, thereby narrowing the gap for eliciting effective immune responses.
Alaunos' drug candidates are built on the scientifically established paradigm that harnessing the power of the immune system can fight cancer. The main product candidates are gavo-cel and TC-110, both being evaluated presently in phase 1/2 clinical trials, and showing promising results. They aim to target multiple antigens covering a vast array of cancers.
Just as the name suggests, Alaunos Therapeutics are pioneers, tirelessly advancing new technologies, innovations, and solutions. These promising agentries not only indicate a promising outlook for the company but also bring renewed hope for patients battling cancer. The company continually works towards exploring and developing new treatment avenues that cater to the needs of a global patient population.
Working at the intersection of high-level science and intimate patient care, Alaunos Therapeutics stands as a beacon in the overwhelmingly competitive biotech industry. Driven by the unyielding motive to elicit tangible, life-altering results and embody its name's essence, Alaunos Therapeutics, Inc., burns with an unwavering resolution. It tackles the dark, daunting landscape of cancer, aiming to provide a glimmer of hope through innovative, groundbreaking therapies.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Alaunos Therapeutics Inc. (TCRT) stock surged significantly after the company completed the acquisition of Velaris Therapeutics and raised $350 million through a private placement. This deal provides Alaunos with a new pipeline, primarily focusing on VLR199 for pulmonary arterial hypertension, and extends its operational runway into 2029, transforming it from a cash-strapped micro-cap into a cash-rich development platform. Traders are reacting to both the reduced financing risk and the momentum-driven trading opportunities created by the news.
Alaunos Therapeutics Inc. (TCRT) stock surged following its acquisition of Velaris Therapeutics and a concurrent $350 million private placement. This capital infusion is expected to fund operations into 2029 and advance Velaris's cardiopulmonary disease pipeline, which includes candidates for pulmonary arterial hypertension. The deals have dramatically reset TCRT's balance sheet, transforming it into a high-momentum story driven by new catalysts and significant funding.
Gibson Dunn advised Velaris Therapeutics on its acquisition by Alaunos Therapeutics, which completed on October 13. This acquisition combines the companies' portfolios, notably integrating Velaris's ActRII-Fc pipeline with Alaunos's existing therapies. The deal was supported by a concurrent private placement, providing significant funding for the combined entity's operations.
Alaunos Therapeutics Inc. (TCRT) stock surged over 100% following its acquisition of Velaris Therapeutics and a successful $350 million private placement. This deal adds a new pipeline of cardiopulmonary disease treatments, including VLR199 for pulmonary arterial hypertension, and extends the company's cash runway into 2029. The significant capital infusion and new pipeline have transformed TCRT from a struggling biotech into a high-momentum stock, though it remains highly volatile.
Alaunos Therapeutics Inc. (NASDAQ: TCRT) saw its stock price surge following the acquisition of Velaris Therapeutics and a significant $350 million private placement. This deal expands Alaunos' pipeline with new biologics for cardiopulmonary diseases and extends its cash runway into 2029, transforming its financial outlook and risk profile. The market reacted with a massive repricing, indicating a shift from a struggling biotech to a momentum-driven small-cap stock.
Alaunos Therapeutics Inc. (TCRT) stock surged after closing a deal for Velaris Therapeutics and raising $350 million in a private placement. This financing is expected to fund TCRT operations into 2029, advancing lead candidate VLR199 for pulmonary arterial hypertension. The market reacted with significant bullish sentiment, though traders are advised to consider potential future dilution from the convertible preferred stock.